$KTNE presenterade i sin Q3 2023 att ”As of September 30, 2023, total cash, cash equivalents and investments were $180.3 million, which is expected to fund current operations into at least the second quarter of 2026.”
Den 13:e november 2023 skrev Foresite och OrbiMed (46.2% ägande) ett brev:
We are writing to outline our intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock (the “Common Shares”) of Kinnate Biopharma Inc. (the “Company”) not already owned by Foresite or OrbiMed in a going-private transaction (a “Transaction”). As you know, Foresite currently beneficially owns approximately 29.2% of the issued and outstanding Common Shares and OrbiMed currently beneficially owns approximately 17.0% of the issued and outstanding Common Shares
Samma företag skrev liknande till Theseus Pharmaceuticals, Inc. $THRX den 22 november 2023:
We are writing to outline our intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock (the “Common Shares”) of Theseus Pharmaceuticals, Inc. (the “Company”) not already owned by Foresite or OrbiMed in a going-private transaction (a “Transaction”). As you know, Foresite currently beneficially owns approximately 12.6 % of the issued and outstanding Common Shares and OrbiMed currently beneficially owns approximately 40.1 % of the issued and outstanding Common Shares.
$THRX mcap: 170M vid 3.86 per aktie
$KTNE mcap: 107M vid 2.28 per aktie
Samma joint venture gjorde liknande (var huvudägare och annonserade deras ”intent to explore acquisition of all shrs”) och lade ett bud på Pardes Biosciences den 17 juli 2023.
De köpte ut Pardes för ca 85% av net cash + en CVR för 80% av ev intäkter från försäljning av verksamhet. Något liknande här skulle bli ca $2.68 exkl. CVR.